创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

杨冲, 张良, 宋晓峰, 李峰, 李文保. 杨梅素及其衍生物研究进展[J]. 药学进展, 2019, 43(3): 217-225.
引用本文: 杨冲, 张良, 宋晓峰, 李峰, 李文保. 杨梅素及其衍生物研究进展[J]. 药学进展, 2019, 43(3): 217-225.
YANG Chong, ZHANG Liang, SONG Xiaofeng, LI Feng, LI Wenbao. Advances in Research on Myricetin and Its Derivatives[J]. Progress in Pharmaceutical Sciences, 2019, 43(3): 217-225.
Citation: YANG Chong, ZHANG Liang, SONG Xiaofeng, LI Feng, LI Wenbao. Advances in Research on Myricetin and Its Derivatives[J]. Progress in Pharmaceutical Sciences, 2019, 43(3): 217-225.

杨梅素及其衍生物研究进展

Advances in Research on Myricetin and Its Derivatives

  • 摘要: 杨梅素是一种天然黄酮类化合物,具有抗氧化、抗炎、抗肿瘤和抗增殖等多种药理作用,但其水溶性、生物利用度及生物活性低,影响了其开发应用。为了获得水溶性好、高效的杨梅素新衍生物,化学家们对其结构进行了大量的优化工作。对杨梅素及其衍生物的研究进展进行综述,以期为进一步的结构优化提供参考。

     

    Abstract: Myricetin is a natural flavonoid compound with multiple pharmacological activities, such as anti-oxidative, anti-inflammatory, anti-carcinogenic and anti-proliferative effects. However, its development and application have been limited by poor water-solubility, low bioavailability and low biological activity. In order to obtain new derivatives of myricetin with good water-solubility and high efficacy, chemists have conducted extensive structural optimization. In this review, the progress in research on myricetin and its analogues was reported, so as to provide reference for further structural optimization.

     

/

返回文章
返回